CR Sanjiu

CR Sanjiu is the consumer-facing brand identity associated with China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., a Shenzhen-based Chinese pharmaceutical company within China Resources Group. The company is best known in China for mass-market over-the-counter medicines carrying the 999 mark, particularly 999 Ganmaoling, a cold and flu medicine, and 999 Piyanping, a topical dermatological product. Its portfolio also extends into prescription medicines, Chinese patent medicines, self-care products, medical nutrition and other health-related categories. The 999 identity is built around broad household recognition, extensive pharmacy distribution and a practical self-medication proposition. Rather than operating solely as a specialist prescription-drug company, CR Sanjiu has developed a diversified model that combines consumer healthcare with pharmaceutical manufacturing and hospital-oriented products. This gives it exposure to both retail channels and institutional healthcare procurement, while allowing the company to use established consumer brands to support repeat purchases in common health categories. The company is part of China Resources Group, a large state-owned enterprise group with businesses spanning consumer products, healthcare, retail, energy and other sectors. The China Resources connection has provided CR Sanjiu with a broader corporate platform and helped integrate the company into a larger healthcare portfolio. CR Sanjiu remains separately listed in Shenzhen under stock code 000999.SZ. Its principal market is mainland China, where products are sold through pharmacies, hospitals, e-commerce platforms and other retail channels. The company’s brand architecture includes the 999 master mark as well as category-specific products and legacy Chinese-medicine brands. Its public positioning emphasizes accessible medicines, self-care and healthcare services, although the exact mix of products and strategic priorities changes over time. CR Sanjiu’s importance in the Chinese consumer-health market comes from the combination of brand familiarity, nationwide distribution and a broad product range. 999 Ganmaoling has become one of the most recognizable Chinese cold-medicine brands, while 999 Piyanping gives the portfolio a strong presence in topical skin treatment. The company also participates in prescription and traditional Chinese medicine categories, making it more diversified than a pure OTC brand. Because reliable source material supplied for this entry does not establish a single definitive founding year, founder, current executive roster or a complete chronological corporate history, those fields are left unreported rather than inferred.

CR Sanjiu developed as a Chinese pharmaceutical enterprise centered on medicines for common illnesses and household healthcare needs. The 999 brand became particularly visible through OTC products distributed widely across Chinese pharmacies and retail channels. Its early consumer recognition was associated with cold remedies, especially 999 Ganmaoling, and later expanded through products such as 999 Piyanping for topical skin conditions. The business subsequently broadened beyond a narrow OTC focus. Its activities came to include prescription pharmaceuticals, Chinese patent medicines, medical nutrition and other healthcare products. This diversification reflected the development of China’s pharmaceutical and retail-healthcare markets, in which manufacturers increasingly sought a balance between hospital sales, pharmacy distribution and direct consumer demand. China Resources became the company’s controlling corporate group, bringing CR Sanjiu into the healthcare portfolio of China Resources Group. The company retained a public-market identity in Shenzhen and continued to operate under the 999 consumer brand alongside its corporate China Resources Sanjiu name. The combination of a recognizable consumer mark and a diversified pharmaceutical platform distinguishes CR Sanjiu from brands that operate only in one therapeutic category. In the contemporary market, CR Sanjiu serves Chinese consumers through a mixture of pharmacies, hospitals, e-commerce and other healthcare channels. Its best-known products remain associated with self-care and everyday ailments, while its wider portfolio supports prescription, traditional Chinese medicine and nutrition businesses. Publicly available material supplied for this dossier does not provide enough verified detail to state a precise founding year, identify a founder, reconstruct every corporate transaction or list current and former executives with confidence. Those details are therefore omitted.

• Development of the 999 consumer-health portfolio

  [1]CR Sanjiu official website999.com.cn

  The 999 mark became strongly associated with widely distributed OTC medicines, including cold remedies and topical dermatological products.

• Integration into China Resources Group

  [1]CR Sanjiu official website999.com.cn

  CR Sanjiu became part of China Resources Group’s broader healthcare interests and continued as a separately listed pharmaceutical company.

• Expansion beyond OTC medicines

  [1]CR Sanjiu official website999.com.cn

  The company broadened its activities into prescription medicines, Chinese patent medicines, medical nutrition and other healthcare categories.

Mass-market OTC, consumer health and diversified pharmaceutical products

• Cold and flu OTC medicine

  999 Ganmaoling

  A widely recognized 999-branded cold medicine sold in China for symptomatic relief associated with common colds and related upper-respiratory complaints. It is one of the products most closely associated with CR Sanjiu’s household brand recognition and pharmacy presence.

• Topical dermatological medicine

  999 Piyanping

  A 999-branded topical skin-treatment line used for common dermatological complaints. Its presence gives CR Sanjiu a recognizable consumer-health position outside cold and flu medicines and contributes to the breadth of the company’s pharmacy portfolio.

• Prescription pharmaceuticals

  CR Sanjiu prescription medicines

  The company also manufactures and markets prescription pharmaceutical products. These products complement its consumer-facing OTC business and connect the company with hospital and professional healthcare channels.

• Traditional Chinese medicine

  CR Sanjiu Chinese patent medicines

  Chinese patent medicines form part of the company’s broader pharmaceutical portfolio. This category extends CR Sanjiu’s participation beyond Western-style OTC products and reflects the continuing importance of traditional Chinese medicine in the Chinese healthcare market.

• Medical nutrition and consumer health

  CR Sanjiu medical nutrition and health products

  CR Sanjiu participates in medical nutrition and related health categories alongside its medicine business. These products broaden the company’s exposure to care, recovery and everyday health needs, although a complete current product list is not established by the supplied sources.

• 2021

  Subsidiary's RMB 164 million in improperly recorded expenses draws maximum penalty from Ministry of Finance

  In 2020 the Ministry of Finance conducted accounting information quality inspections of 77 pharmaceutical companies and announced the results in 2021: China Resources Sanjiu's wholly owned subsidiary Shenzhen China Resources Sanjiu Pharmaceutical Trading Co., Ltd. in 2018 had improperly recorded expenses for video production, logistics supervision, meetings and research, involving about RMB 164 million, and was fined RMB 50,000 at the maximum. Hengrui Pharmaceuticals, Shanghai Pharmaceuticals, Buchang Pharmaceuticals and 19 other drug companies were also on the "blacklist." Media widely questioned the commercial bribery risks behind huge "promotion fees," pushing compliance rectification in the pharmaceutical industry.

  Source

• 2015

  China Resources Sanjiu subsidiary's Shuxuening Injection fails spot check; recalled and production and sales suspended

  Securities Times reported that a spot check on February 17, 2015 found two batches of Shuxuening Injection from China Resources Gaoke failed. The company recalled the relevant batches and proactively expanded the recall, suspended production and sales of the product, and carried out risk assessment and rectification. The company said at the time it had not received reports of serious adverse reactions. Progress: the company announcement confirmed the recall and suspension of production and sales. Subjects involved: Beijing China Resources Gaoke Natural Medicine Co., Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Scope: the Shuxuening product incident at subsidiary Beijing China Resources Gaoke Natural Medicine.

  Source

Read more

• 2021.12.03

  Reported2021.12.12

  China Resources Sanjiu chairman resigns[5]华润三九董事长辞职finance.sina.com.cn

  China Resources Sanjiu said chairman Wang Chuncheng resigned as chairman and director due to a work change and would hold no further positions at the company.

• 2020.08.22

  Dong-E-E-Jiao and China Resources Sanjiu launch Ejiao Pearl tablets[6]东阿阿胶携手华润三九推出阿胶珠中药饮片f.sdnews.com.cn

  Dong-E-E-Jiao and China Resources Sanjiu launched a new Ejiao Pearl traditional Chinese medicine product and said the launch was intended to deepen their presence in medical channels.

• 2019.11.28

  Reported2019.11.28

  China Resources Sanjiu announces planned acquisition of Aonuo Pharmaceutical[7]华润三九公告拟收购澳诺制药finance.sina.com.cn

  China Resources Sanjiu announced that it plans to acquire 100% of Aonuo (China) Pharmaceutical Co., Ltd. from Yuheng Pharma for RMB 1.42 billion. The article says the acquisition had not yet been completed.

• 2019.10.23

  Reported2019.10.30

  China Resources Sanjiu and Takeda Consumer Health sign Alinamin agreement for China[8]华润三九与武田消费者健康公司签署爱利纳明中国市场合作协议finance.sina.com.cn

  China Resources Sanjiu and Takeda Consumer Health signed an agreement under which China Resources Sanjiu will handle commercialization and sales of Takeda's Alinamin brand in China.

Read more

1. 1CR Sanjiu official website999.com.cn
2. 2China Resources Sanjiu subsidiary's Shuxuening Injection fails spot check; recalled and production and sales suspendedepaper.stcn.com
3. 3Subsidiary's RMB 164 million in improperly recorded expenses draws maximum penalty from Ministry of Financejiemian.com
4. 4Subsidiary's RMB 164 million in improperly recorded expenses draws maximum penalty from Ministry of Financefinance.sina.com.cn
5. 5华润三九董事长辞职finance.sina.com.cn
6. 6东阿阿胶携手华润三九推出阿胶珠中药饮片f.sdnews.com.cn
7. 7华润三九公告拟收购澳诺制药finance.sina.com.cn
8. 8华润三九与武田消费者健康公司签署爱利纳明中国市场合作协议finance.sina.com.cn